If you are Texas Children’s Health Plan Member, we have tips that can help you deal with the severe weather. Learn more
Si eres miembro de Texas Children’s Health Plan, tenemos consejos que pueden ayudarte a lidiar con el clima severo. Aprende Más
Date: October 4, 2024
Attention: Providers
Effective date: October 10, 2024
Call to action: On September 25, 2024, Pfizer, the manufacturer voluntarily recalled all Oxbryta® (voxelotor) products from worldwide markets due to safety concerns.
Oxbryta will no longer be a covered benefit and will no longer be on the formulary starting October 17, 2024.
| Product | NDC No. |
| OXBRYTA 500 MG TABLET | 72786010101 |
| OXBRYTA 300 MG TABLET FOR SUSP | 72786011102 |
| OXBRYTA 300 MG TABLET FOR SUSP | 72786011103 |
| OXBRYTA 300 MG TABLET | 72786010202 |
| OXBRYTA 300 MG TABLET | 72786010203 |
Next step for Providers: Providers should inform their impacted patients and arrange for the return and replacement of the drug.
If you have any questions, please email Provider Relations at: providerrelations@texaschildrens.org.
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.